Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Uricase and other novel agents for the management of patients with treatment-failure gout.

Publication ,  Journal Article
Sundy, JS; Hershfield, MS
Published in: Curr Rheumatol Rep
June 2007

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Rheumatol Rep

DOI

ISSN

1523-3774

Publication Date

June 2007

Volume

9

Issue

3

Start / End Page

258 / 264

Location

United States

Related Subject Headings

  • Uric Acid
  • Urate Oxidase
  • Treatment Failure
  • Thiazoles
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Humans
  • Gout Suppressants
  • Gout
  • Febuxostat
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sundy, J. S., & Hershfield, M. S. (2007). Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep, 9(3), 258–264. https://doi.org/10.1007/s11926-007-0041-y
Sundy, John S., and Michael S. Hershfield. “Uricase and other novel agents for the management of patients with treatment-failure gout.Curr Rheumatol Rep 9, no. 3 (June 2007): 258–64. https://doi.org/10.1007/s11926-007-0041-y.
Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007 Jun;9(3):258–64.
Sundy, John S., and Michael S. Hershfield. “Uricase and other novel agents for the management of patients with treatment-failure gout.Curr Rheumatol Rep, vol. 9, no. 3, June 2007, pp. 258–64. Pubmed, doi:10.1007/s11926-007-0041-y.
Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep. 2007 Jun;9(3):258–264.
Journal cover image

Published In

Curr Rheumatol Rep

DOI

ISSN

1523-3774

Publication Date

June 2007

Volume

9

Issue

3

Start / End Page

258 / 264

Location

United States

Related Subject Headings

  • Uric Acid
  • Urate Oxidase
  • Treatment Failure
  • Thiazoles
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Humans
  • Gout Suppressants
  • Gout
  • Febuxostat